Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

the treatment of cancer.  VAL-083 has been assessed in multiple clinical studies sponsored by the National Cancer Institute (NCI) in the United States as a treatment against various cancers including lung, brain, cervical, ovarian tumors and leukemia.  Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.  VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer.

DelMar is currently conducting a Phase I/II clinical trial with VAL-083 as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  In April 2012, DelMar presented data at the American Association of Cancer Research (AACR website:  http://www.aacr.org) annual meeting demonstrating that VAL-083 maintains activity in tumors resistant to the current front-line GBM therapy, Temodar®.  In November 2012, DelMar presented interim data from the ongoing GBM clinical trial at the Annual Meeting of the Society for NeuroOncology (SNO website:  http://www.soc-neuro-onc.org) demonstrating that VAL-083 can shrink or halt the growth of tumors in brain cancer patients who have failed other approved treatments.  Currently, there is no approved therapy for these patients. 

In addition to the Company's clinical development activities in the United States, DelMar has obtained exclusive commercial rights to VAL-083 in China.  In October 2012, DelMar announced a collaboration agreement with the only manufacturer presently licensed by the Chinese State Food and Drug Administration (SFDA) to produce VAL-083 for the China market.  This agreement provides DelMar with exclusive commercial right
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... OncLive® is pleased to announce ... its Strategic Alliance Partnership program. , By ... Lineberger will have the opportunity to work with ... cutting-edge research initiatives, community-directed cancer prevention programs, and ... with OncLive to educate their peers by providing ...
(Date:7/23/2014)... Boston, MA (PRWEB) July 23, 2014 ... regenerative medicine transplant therapies are biological, but not ... trials may seem to treat them as if ... as well as unsanctioned studies that constitute “stem ... transplantation as an approach to developing new regenerative ...
(Date:7/22/2014)... Web) July 21, 2014 (PRWEB) July 23, 2014 ... Biomaterials, at Rutgers University. , The goal ... ideas across the full spectrum of scientists working ... research and development topics that represent the most ... been programmed to:,     Provide faculty ...
(Date:7/22/2014)... 22, 2014 Even within a phylum so full of ... among other arthropods for its cruelty -- at least to ... the fly is a most predatory sort of parasite. It ... a smear of larvae, and leaves its wicked brood to ... , None of this would be possible without the fly,s ...
Breaking Biology Technology:OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4
... , NES-ZIONA, Israel, July 27, PROLOR ... that it has entered into an evaluation and option agreement with ... the Weizmann Institute of Science . Under ... from Yeda a license to develop a number of peptide drug ...
... , , , ... medicine is just in its adolescence today and I see our ... applications and global markets," stated Edward Pulwer, upon accepting the position ... Sechrist has been in business for over 30 ...
... , CALGARY, July 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... with the support of its contract manufacturer, SAFC Pharma(R), ... an initial 100-litre production run of REOLYSIN under cGMP ... of a series to be completed over the next ...
Cached Biology Technology:PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug 2PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug 3Sechrist Industries, World Leader in Hyperbaric Chambers, Announces Edward Pulwer as President/CEO 2Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R) 2
(Date:7/23/2014)... especially the young, are highly sensitive to temperature and ... temperatures within a narrow range. Recently published research led ... School of Arts and Sciences, is the first to ... hive in process similar to how humans and other ... , "This study shows how workers effectively dissipate ...
(Date:7/23/2014)... fur seals, alongside decades of in-depth monitoring, has ... change on a population of top-predators. Published in ... that the seals have significantly altered in accordance ... with climate conditions. Despite a shift in the ... passing down through generations, leaving the population in ...
(Date:7/23/2014)... experiments using tissue samples cultured from cystic fibrosis patients, ... UNC Marsico Lung Institute have shown that a new ... another CF drug. , The finding, published today in ... a mutant CFTR protein becomes unstable and loses its ... the two drugs. The research offers several insights into ...
Breaking Biology News(10 mins):How honey bees stay cool 2Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... by Princeton University engineers could harness natural body ... pacemakers, mobile phones and other electronic devices. ... silicone rubber sheets, generates electricity when flexed and ... electrical energy. Shoes made of the material may ...
... by researchers with the U.S. Department of Energy,s Joint ... produce an advanced biofuel directly from biomass. Deploying the ... strain of Escherichia coli ( E. coli ) bacteria ... from fatty acids. "The fact that our microbes ...
... recent study at Oregon State University indicates that some past ... overestimated the number of live trees that burn up and ... a result. The research was done on the Metolius ... one-third or 100,000 acres of the area burned ...
Cached Biology News:Energy-harvesting rubber sheets could power pacemakers, mobile phones 2Microbes produce fuels directly from biomass 2Microbes produce fuels directly from biomass 3Effects of forest fire on carbon emissions, climate impacts often overestimated 2Effects of forest fire on carbon emissions, climate impacts often overestimated 3
...
... 4 deuterium atoms at the 3, 3', ... for use as an internal standard for ... LC-mass spectrometry. PGE1 is the theoretical cyclooxygenase ... is virtually undetectable in the plasma of ...
Direct ELISA Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Biology Products: